{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:27:15Z","timestamp":1789698435920,"version":"4.0.1"},"reference-count":57,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T00:00:00Z","timestamp":1613260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Epidermal growth factor receptor (EGFR) specific therapeutics is of great importance in cancer treatment. Fcy-hEGF fusion protein, composed of yeast cytosine deaminase (Fcy) and human EGF (hEGF), is capable of binding to EGFR and enzymatically convert 5-fluorocytosine (5-FC) to 1000-fold toxic 5-fluorocuracil (5-FU), thereby inhibiting the growth of EGFR-expressing tumor cells. To develop EGFR-specific therapy, 188Re-liposome-Fcy-hEGF was constructed by insertion of Fcy-hEGF fusion protein onto the surface of liposomes encapsulating of 188Re. Western blotting, MALDI-TOF, column size exclusion and flow cytometry were used to confirm the conjugation and bio-activity of 188Re-liposome-Fcy-hEGF. Cell lines with EGFR expression were subjected to treat with 188Re-liposome-Fcy-hEGF\/5-FC in the presence of 5-FC. The 188Re-liposome-Fcy-hEGF\/5-FC revealed a better cytotoxic effect for cancer cells than the treatment of liposome-Fcy-hEGF\/5-FC or 188Re-liposome-Fcy-hEGF alone. The therapeutics has radio- and chemo-toxicity simultaneously and specifically target to EGFR-expression tumor cells, thereby achieving synergistic anticancer activity.<\/jats:p>","DOI":"10.3390\/ijms22041902","type":"journal-article","created":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T08:53:56Z","timestamp":1613292836000},"page":"1902","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Bi-Functional Radiotheranostics of 188Re-Liposome-Fcy-hEGF for Radio- and Chemo-Therapy of EGFR-Overexpressing Cancer Cells"],"prefix":"10.3390","volume":"22","author":[{"given":"Yi-Shu","family":"Huang","sequence":"first","affiliation":[{"name":"Division of Isotope Application, Institute of Nuclear Energy Research, Taoyuan 32546, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chuan","family":"Hsu","sequence":"additional","affiliation":[{"name":"Division of Isotope Application, Institute of Nuclear Energy Research, Taoyuan 32546, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hong","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Isotope Application, Institute of Nuclear Energy Research, Taoyuan 32546, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Nan","family":"Lo","sequence":"additional","affiliation":[{"name":"Division of Isotope Application, Institute of Nuclear Energy Research, Taoyuan 32546, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu-Nian","family":"Cheng","sequence":"additional","affiliation":[{"name":"Division of Isotope Application, Institute of Nuclear Energy Research, Taoyuan 32546, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Syuan","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Isotope Application, Institute of Nuclear Energy Research, Taoyuan 32546, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Te-Wei","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Isotope Application, Institute of Nuclear Energy Research, Taoyuan 32546, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hsien","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Isotope Application, Institute of Nuclear Energy Research, Taoyuan 32546, Taiwan"},{"name":"Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keng-Li","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of Oncology, Taipei Veterans General Hospital, Taipei 112, Taiwan"},{"name":"Institute of Traditional Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/2472630317738699","article-title":"Theranostic Nanoparticles for Tracking and Monitoring Disease State","volume":"23","author":"Zavaleta","year":"2018","journal-title":"SLAS Technol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd2614","article-title":"Nanoparticle therapeutics: An emerging treatment modality for cancer","volume":"7","author":"Davis","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrd1632","article-title":"Recent advances with liposomes as pharmaceutical carriers","volume":"4","author":"Torchilin","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Lamichhane, N., Udayakumar, T.S., D\u2019Souza, W.D., Simone, C.B., Raghavan, S.R., Polf, J., and Mahmood, J. (2018). Liposomes: Clinical Applications and Potential for Image-Guided Drug Delivery. Molecules, 23.","DOI":"10.3390\/molecules23020288"},{"key":"ref_5","first-page":"49","article-title":"Clinical development of liposome-based drugs: Formulation, characterization, and therapeutic efficacy","volume":"7","author":"Chang","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/sj.clpt.6100400","article-title":"Nanoparticles in medicine: Therapeutic applications and developments","volume":"83","author":"Zhang","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.addr.2019.05.012","article-title":"Nuclear imaging of liposomal drug delivery systems: A critical review of radiolabelling methods and applications in nanomedicine","volume":"143","author":"Man","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1080\/17425247.2016.1205584","article-title":"Radionuclide imaging of liposomal drug delivery","volume":"13","author":"Laverman","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/00006231-199609000-00004","article-title":"Labelled Stealth liposomes in experimental infection: An alternative to leukocyte scintigraphy?","volume":"17","author":"Oyen","year":"1996","journal-title":"Nucl. Med. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-1-4939-6591-5_13","article-title":"Techniques for Loading Technetium-99m and Rhenium-186\/188 Radionuclides into Preformed Liposomes for Diagnostic Imaging and Radionuclide Therapy","volume":"1522","author":"Goins","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3389\/fmed.2019.00132","article-title":"Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives","volume":"6","author":"Lepareur","year":"2019","journal-title":"Front. Med. (Lausanne)"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10637-012-9906-7","article-title":"Therapeutic efficacy of 188Re-liposome in a C26 murine colon carcinoma solid tumor model","volume":"31","author":"Chang","year":"2013","journal-title":"Investig. New Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.nucmedbio.2011.06.010","article-title":"Pharmacokinetics, dosimetry and comparative efficacy of 188Re-liposome and 5-FU in a CT26-luc lung-metastatic mice model","volume":"39","author":"Chen","year":"2012","journal-title":"Nucl. Med. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13550-019-0509-6","article-title":"A phase 0 study of the pharmacokinetics, biodistribution, and dosimetry of 188Re-liposome in patients with metastatic tumors","volume":"9","author":"Wang","year":"2019","journal-title":"EJNMMI Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Chang, C.M., Lan, K.L., Huang, W.S., Lee, Y.J., Lee, T.W., Chang, C.H., and Chuang, C.M. (2017). 188Re-Liposome Can Induce Mitochondrial Autophagy and Reverse Drug Resistance for Ovarian Cancer: From Bench Evidence to Preliminary Clinical Proof-of-Concept. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18050903"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jconrel.2010.11.018","article-title":"Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: Formulation design, pharmacokinetics and efficacy","volume":"150","author":"Thomas","year":"2011","journal-title":"J. Control Release"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1007\/s11095-006-9113-3","article-title":"Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: Implications for tumor vascular targeting","volume":"23","author":"Kalra","year":"2006","journal-title":"Pharm. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s10544-009-9328-2","article-title":"Novel PEG-coated niosomes based on bola-surfactant as drug carriers for 5-fluorouracil","volume":"11","author":"Cosco","year":"2009","journal-title":"Biomed. Microdevices"},{"key":"ref_19","first-page":"1069","article-title":"Skin delivery of 5-fluorouracil from ultradeformable and standard liposomes in-vitro","volume":"53","author":"Williams","year":"2001","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.3748\/wjg.v11.i17.2643","article-title":"Anti-hepatocarcinoma effects of 5-fluorouracil encapsulated by galactosylceramide liposomes in vivo and in vitro","volume":"11","author":"Jin","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"ref_21","first-page":"2607","article-title":"Biodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice","volume":"6","author":"Tsai","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3109\/10717544.2010.500635","article-title":"Development and characterization of hyaluronic acid decorated PLGA nanoparticles for delivery of 5-fluorouracil","volume":"17","author":"Yadav","year":"2010","journal-title":"Drug Deliv."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/jac\/46.2.171","article-title":"Flucytosine: A review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions","volume":"46","author":"Vermes","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.bbrc.2012.10.050","article-title":"5-Fluorocytosine combined with Fcy-hEGF fusion protein targets EGFR-expressing cancer cells","volume":"428","author":"Lan","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.2174\/1389557513666131119202717","article-title":"Antibody-targeted immunoliposomes for cancer treatment","volume":"13","author":"Gao","year":"2013","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(12)70476-X","article-title":"Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: A phase 1 dose-escalation study","volume":"13","author":"Mamot","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_27","first-page":"4777","article-title":"Cytotoxic Effects of PEGylated Anti-EGFR Immunoliposomes Combined with Doxorubicin and Rhenium-188 Against Cancer Cells","volume":"35","author":"Hsu","year":"2015","journal-title":"Anticancer Res."},{"key":"ref_28","first-page":"1417","article-title":"Superiority of yeast over bacterial cytosine deaminase for enzyme\/prodrug gene therapy in colon cancer xenografts","volume":"59","author":"Kievit","year":"1999","journal-title":"Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1158\/0008-5472.CAN-05-1578","article-title":"Endostatin-cytosine deaminase fusion protein suppresses tumor growth by targeting neovascular endothelial cells","volume":"66","author":"Lan","year":"2006","journal-title":"Cancer Res."},{"key":"ref_30","first-page":"951","article-title":"Design, construction, and in vitro analysis of A33scFv::CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer","volume":"31","author":"Coelho","year":"2007","journal-title":"Int. J. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1021\/mp800013c","article-title":"Antitumor therapy mediated by 5-fluorocytosine and a recombinant fusion protein containing TSG-6 hyaluronan binding domain and yeast cytosine deaminase","volume":"6","author":"Park","year":"2009","journal-title":"Mol. Pharm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3892\/ijo_32_6_1245","article-title":"Genetic construction, expression, and characterization of a single chain anti-CEA antibody fused to cytosine deaminase from yeast","volume":"32","author":"Zamboni","year":"2008","journal-title":"Int. J. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.radonc.2012.07.011","article-title":"Hypoxia targeted bifunctional suicide gene expression enhances radiotherapy in vitro and in vivo","volume":"105","author":"Sun","year":"2012","journal-title":"Radiother. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.canlet.2011.03.016","article-title":"Annexin V-targeted enzyme prodrug therapy using cytosine deaminase in combination with 5-fluorocytosine","volume":"307","author":"Harrison","year":"2011","journal-title":"Cancer Lett."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.mt.6300190","article-title":"The suicide gene therapy challenge: How to improve a successful gene therapy approach","volume":"15","author":"Bonini","year":"2007","journal-title":"Mol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jmb.2008.01.002","article-title":"Yeast cytosine deaminase mutants with increased thermostability impart sensitivity to 5-fluorocytosine","volume":"377","author":"Stolworthy","year":"2008","journal-title":"J. Mol. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/bjc.1996.373","article-title":"Comparative alterations in p53 expression and apoptosis in the irradiated rat small and large intestine","volume":"74","author":"Arai","year":"1996","journal-title":"Br. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1126\/science.7973635","article-title":"p53 status and the efficacy of cancer therapy in vivo","volume":"266","author":"Lowe","year":"1994","journal-title":"Science"},{"key":"ref_39","first-page":"614","article-title":"The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice","volume":"54","author":"Merritt","year":"1994","journal-title":"Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0092-8674(92)90421-8","article-title":"p53 function and dysfunction","volume":"70","author":"Vogelstein","year":"1992","journal-title":"Cell"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/362847a0","article-title":"p53 is required for radiation-induced apoptosis in mouse thymocytes","volume":"362","author":"Lowe","year":"1993","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/362849a0","article-title":"Thymocyte apoptosis induced by p53-dependent and independent pathways","volume":"362","author":"Clarke","year":"1993","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF00048063","article-title":"The significance of spontaneous and induced apoptosis in the gastrointestinal tract of mice","volume":"11","author":"Potten","year":"1992","journal-title":"Cancer Metastasis Rev."},{"key":"ref_44","first-page":"479","article-title":"Unique radiosensitivity of serous cells in rhesus monkey submandibular glands","volume":"124","author":"Stephens","year":"1986","journal-title":"Am. J. Pathol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2307\/3577641","article-title":"Response of parotid gland organ culture to radiation","volume":"120","author":"Stephens","year":"1989","journal-title":"Radiat. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2307\/3578399","article-title":"Development of apoptosis in irradiated murine tumors as a function of time and dose","volume":"135","author":"Stephens","year":"1993","journal-title":"Radiat. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0959-8049(92)90104-A","article-title":"Effects of extracellular matrix on the response of endothelial cells to radiation in vitro","volume":"28A","author":"Fuks","year":"1992","journal-title":"Eur. J. Cancer"},{"key":"ref_48","first-page":"2582","article-title":"Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo","volume":"54","author":"Fuks","year":"1994","journal-title":"Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00259-003-1216-z","article-title":"Beta-irradiation used for systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in leukaemia cells","volume":"30","author":"Friesen","year":"2003","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.radonc.2016.02.007","article-title":"Intraperitoneal (188)Re-Liposome delivery switches ovarian cancer metabolism from glycolysis to oxidative phosphorylation and effectively controls ovarian tumour growth in mice","volume":"119","author":"Shen","year":"2016","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41420-018-0116-8","article-title":"PEGylated liposome-encapsulated rhenium-188 radiopharmaceutical inhibits proliferation and epithelial-mesenchymal transition of human head and neck cancer cells in vivo with repeated therapy","volume":"4","author":"Chang","year":"2018","journal-title":"Cell Death Discov."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"65782","DOI":"10.18632\/oncotarget.11666","article-title":"Involvement of let-7 microRNA for the therapeutic effects of Rhenium-188-embedded liposomal nanoparticles on orthotopic human head and neck cancer model","volume":"7","author":"Lin","year":"2016","journal-title":"Oncotarget"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/(SICI)1097-0215(19990301)80:5<723::AID-IJC16>3.0.CO;2-L","article-title":"Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model","volume":"80","author":"Tseng","year":"1999","journal-title":"Int. J. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"11631","DOI":"10.1158\/0008-5472.CAN-05-1093","article-title":"Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo","volume":"65","author":"Mamot","year":"2005","journal-title":"Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1194\/jlr.D800043-JLR200","article-title":"A novel flow cytometric assay to quantify interactions between proteins and membrane lipids","volume":"50","author":"Temmerman","year":"2009","journal-title":"J. Lipid Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0021-9258(18)70226-3","article-title":"Phosphorus assay in column chromatography","volume":"234","author":"Bartlett","year":"1959","journal-title":"J. Biol. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.nucmedbio.2007.02.003","article-title":"Biodistribution, pharmacokinetics and imaging of 188Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model","volume":"34","author":"Chen","year":"2007","journal-title":"Nucl. Med. Biol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/4\/1902\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:24:11Z","timestamp":1760160251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/4\/1902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,14]]},"references-count":57,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["ijms22041902"],"URL":"https:\/\/doi.org\/10.3390\/ijms22041902","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,14]]}}}